Table: Sawai Pharmaceutical -6-MTH group results (IFRS)

SAWAI group

08/11/2019 06:00

Nov 8 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2019        Sep 30, 2018     Mar 31, 2020 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               90.48               88.79           184.40    
                   (+1.9 pct)          (+11.0 pct)      (+0.0 pct)  
  Operating           15.26               13.77            25.80    
                   (+10.8 pct)         (+2.5 pct)       (+0.0 pct)  
  Pretax              15.15               13.69            25.70    
                   (+10.7 pct)         (-1.7 pct)       (+0.1 pct)  
  Net                 10.97               10.52            19.20    
                   (+4.3 pct)          (-2.5 pct)       (-0.9 pct)  
  EPS Basic        250.61 yen          240.25 yen       438.53 yen  
  EPS Diluted      250.42 yen          240.10 yen                   
  Ann Div                              135.00 yen       130.00 yen  
  -Q2 Div           65.00 yen           65.00 yen                   
  -Q4 Div                               70.00 yen        65.00 yen  
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T